氯苯吩嗪抗结核作用的研究进展  

Advance in anti-tuberculous activity of clofazimine

作　　者：左小淑 陆宇[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所药物研究室,101149

出　　处：《中国防痨杂志》2015年第1期90-94,共5页Chinese Journal of Antituberculosis

摘　　要：氯苯吩嗪是一种吩嗪类衍生物，具有抗微生物活性，最初被用来治疗麻风病。近年来发现其具有很强的体内外抗结核活性，尤其是其对多耐药结核分枝杆菌菌株具有杀菌活性，相关研究也证实了该药对治疗多耐药和广泛耐药结核病具有很好的前景，其抗结核作用新靶点和作用机制的研究是近年的热点。本研究旨在介绍氯苯吩嗪抗结核作用的药理学特性及其临床应用情况，并重点阐述其抗结核作用机制的研究进展。Clofazimine, a phenazine derivative possessing antimicrobial activity, was originally used to cure leprosy. Recently it has been found that clofazimine has potency against Mycobacteriurn tubezculosis, especially for multidrug-resistant strains. Related studies showed clofazimine has good potency in the treatment of multidrug and extensively multidrug-resistant tuberculosis. Thereby, study on the new targets and mechanisms of clofazimine have become the research hotspot in recent years. This review aims to introduce the latest advancement of clofazimine in terms of pharmacological properties and clinical applications, focusing on the mechanisms of anti-tuberculous action.

关 键 词：分枝杆菌 结核 抗结核药 氯苯吩嗪 

分 类 号：R978.3[医药卫生—药品]